FDA screw-over on the Nasal. Exclusivity shows up in November 2016, for a product not even available. Yet EGLT also has a nasal product, which means the other company didn't deserve it. Even the analyst didn't know about it.
IMO the FDA is on the take!
The only abuse deterrent IMO, is making the patient go to a clinic to receive it each time.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.